VICENTE
ESTRADA PÉREZ
Profesor asociado de Ciencias de la Salud
MARÍA
DE LAGARDE SEBASTIÁN
Profesora asociada de Ciencias de la Salud
Publicacions en què col·labora amb MARÍA DE LAGARDE SEBASTIÁN (9)
2023
-
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
2021
-
Blood Bacterial Profiles Associated With Human Immunodeficiency Virus Infection and Immune Recovery
The Journal of infectious diseases, Vol. 223, Núm. 3, pp. 471-481
2020
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
2019
-
Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study)
Clinical Infectious Diseases, Vol. 68, Núm. 1, pp. 120-130
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
2015
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792